AGP Executive Report
Last update: 10 hours agoCancer Care in Europe: The EU has approved Gilead’s Trodelvy (sacituzumab govitecan) as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 inhibitors, with approval also covering Iceland. Bladder Cancer Update: The European Commission also cleared MSD’s Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with use across the EU plus Iceland, Norway and Liechtenstein. Youth Substance Abuse Prevention (Iceland-linked): Planet Youth, a prevention model developed in Iceland, is set to roll out in Canada’s Algoma region schools after nearly $600,000 in funding, aiming to reduce early alcohol and drug harm using local grade-10 survey data. Public Health Policy: The Netherlands reported health spending up 6.1% in 2025, while long-term care is rising fastest. Health & Travel Safety: UK airport guidance warns travellers not to bring certain meat and dairy products back from the EU due to animal disease risk, with fines for undeclared items. Global Children’s Rights: Iceland ranks near the top in a new children’s rights index, while Afghanistan is last.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
